Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present NewLink Genetics Corp (NASDAQ: NLNK).

Full DD Report for NLNK

You must become a subscriber to view this report.


Recent News from (NASDAQ: NLNK)

NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback
We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger NewLink Genetics (NASDAQ: NLNK...
Source: SeekingAlpha
Date: May, 17 2018 05:16
NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018
AMES, Iowa, May 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two Phase 2 studies of indoximod, used in combination with other agents, are now available on the website of the  2018 American Society of Clinical Oncolog...
Source: GlobeNewswire
Date: May, 16 2018 17:00
Roche backs out of IDO inhibitor development deal with NewLink
Roche's ( OTCQX:RHHBY ) Genentech unit is the latest company to back away from IDO inhibition for the treatment of cancer. On May 10, it notified collaboration partner NewLink Genetics (NASDAQ: NLNK ) that will terminate their October 2014 agreement to develop IDO/TDO inhibitors effective ...
Source: SeekingAlpha
Date: May, 15 2018 08:57
NewLink Genetics Corporation 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by NewLink Genetics Corporation in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 04 2018 14:00
3 Things In Biotech, May 3: Bristol Bows Out Of IDO, And Two Biotechs Look To Investigate Novel Immunotherapies
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated...
Source: SeekingAlpha
Date: May, 04 2018 08:00
NewLink Genetics' (NLNK) CEO Charles Link on Q1 2018 Results - Earnings Call Transcript
NewLink Genetics Corporation (NLNK) Q1 2018 Earnings Conference Call May 3, 2018 4:30 PM ET Executives Jack Henneman – Chief Financial Officer Charles Link – Chairman and Chief Executive Officer Eugene Kennedy – Chief Medical Officer Analysts Mara Golds...
Source: SeekingAlpha
Date: May, 03 2018 22:06
NewLink Genetics Reports First Quarter 2018 Financial Results
AMES, Iowa, May 03, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the first quarter 2018 and reviewed recent highlights and upcoming milestones. “NewLink Genetics continues to produce encouraging data suppor...
Source: GlobeNewswire
Date: May, 03 2018 16:01
Developers backing away from IDO inhibitors after Incyte's epacadostat flop
The fallout from Incyte's ( INCY +0.7% ) failed Phase 3 study of IDO inhibitor epacadostat in melanoma has spread to its collaboration partners. More news on: Incyte Corporation, Merck & Co Inc., Bristol-Myers Squibb Company, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 01 2018 10:04
NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
AMES, Iowa, May 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Matthew L. Sherman, M.D. to the Company's Board of Directors.  In connection with this appointment, the Company's Board will be comprised of eight directors. ...
Source: GlobeNewswire
Date: May, 01 2018 09:00
NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting
AMES, Iowa, April 25, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported that two abstracts pertaining to the company's indoximod program will be presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago. ...
Source: GlobeNewswire
Date: April, 25 2018 15:55

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-152.822.762.822.66684,850
2018-08-143.012.813.032.78785,119
2018-08-133.013.013.112.94520,493
2018-08-103.093.013.122.97408,871
2018-08-093.073.093.193.0461519,729

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-15146,064227,09464.3187Short
2018-08-14114,184235,64348.4564Short
2018-08-1370,771212,60033.2883Cover
2018-08-1058,190113,52751.2565Short
2018-08-0992,712169,96654.5474Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NLNK.


About NewLink Genetics Corp (NASDAQ: NLNK)

Logo for NewLink Genetics Corp (NASDAQ: NLNK)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: NLNK)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 15 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 01 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 25 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 19 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 19 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 17 2018

       

       


      Daily Technical Chart for (NASDAQ: NLNK)

      Daily Technical Chart for (NASDAQ: NLNK)


      Stay tuned for daily updates and more on (NASDAQ: NLNK)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: NLNK)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NLNK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of NLNK and does not buy, sell, or trade any shares of NLNK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/